A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Dec 10

PMID 34885957

Citations 24

Authors

Mohammed I El-Gamal

Nada H Mewafi

Nada E Abdelmotteleb

Minnatullah A Emara

Hamadeh Tarazi

Rawan M Sbenati

Moustafa M Madkour

Seyed-Omar Zaraei

Afnan I Shahin

Hanan S Anbar

Affiliations

Soon will be listed here.

Abstract

HER4 is a receptor tyrosine kinase that is required for the evolution of normal body systems such as cardiovascular, nervous, and endocrine systems, especially the mammary glands. It is activated through ligand binding and activates MAPKs and PI3K/AKT pathways. HER4 is commonly expressed in many human tissues, both adult and fetal. It is important to understand the role of HER4 in the treatment of many disorders. Many studies were also conducted on the role of HER4 in tumors and its tumor suppressor function. Mostly, overexpression of HER4 kinase results in cancer development. In the present article, we reviewed the structure, location, ligands, physiological functions of HER4, and its relationship to different cancer types. HER4 inhibitors reported mainly from 2016 to the present were reviewed as well.

Citing Articles

Progress in Precision Medicine for Head and Neck Cancer.

Vakili S, Behrooz A, Whichelo R, Fernandes A, Emwas A, Jaremko M Cancers (Basel). 2024; 16(21).

PMID: 39518152 PMC: 11544984. DOI: 10.3390/cancers16213716.

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.

Gibson J, Pengelly R, Mirandari A, Boukas K, Stanford S, Cecil T Cancer Med. 2024; 13(20):e70340.

PMID: 39435876 PMC: 11494485. DOI: 10.1002/cam4.70340.

RFC2 may contribute to the pathogenicity of Williams syndrome revealed in a zebrafish model.

Park J, Choi T, Kim T, Lee Y, Wellalage Don D, George-Abraham J J Genet Genomics. 2024; 51(12):1389-1403.

PMID: 39368701 PMC: 11624490. DOI: 10.1016/j.jgg.2024.09.016.

HER4 is a high-affinity dimerization partner for all EGFR/HER/ErbB family proteins.

Kumar Singh P, Kim S, Smith A Protein Sci. 2024; 33(10):e5171.

PMID: 39276020 PMC: 11401057. DOI: 10.1002/pro.5171.

Genome-wide association reveals a locus in neuregulin 3 associated with gabapentin efficacy in women with chronic pelvic pain.

Mackenzie S, Rahmioglu N, Romaniuk L, Collins F, Coxon L, Whalley H iScience. 2024; 27(8):110370.

PMID: 39258169 PMC: 11384074. DOI: 10.1016/j.isci.2024.110370.

References

Walker R . The erbB/HER type 1 tyrosine kinase receptor family. J Pathol. 1998; 185(3):234-5. DOI: 10.1002/(SICI)1096-9896(199807)185:3<234::AID-PATH128>3.0.CO;2-8. View

Thien C, Langdon W . Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl. Oncogene. 1998; 15(24):2909-19. DOI: 10.1038/sj.onc.1201468. View

Rauf F, Festa F, Park J, Magee M, Eaton S, Rinaldi C . Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner. Oncogene. 2018; 37(17):2237-2250. PMC: 5916919. DOI: 10.1038/s41388-017-0079-x. View

Wang X, Wong J, Sevinsky C, Kokabee L, Khan F, Sun Y . Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Mol Cancer Ther. 2016; 15(9):2198-208. PMC: 5145257. DOI: 10.1158/1535-7163.MCT-15-0813. View

Gullick W . c-erbB-4/HER4: friend or foe?. J Pathol. 2003; 200(3):279-81. DOI: 10.1002/path.1335. View

Lemmon M, Bu Z, Ladbury J, Zhou M, Pinchasi D, Lax I . Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 1997; 16(2):281-94. PMC: 1169635. DOI: 10.1093/emboj/16.2.281. View

Hynes N, MacDonald G . ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21(2):177-84. DOI: 10.1016/j.ceb.2008.12.010. View

Carraway 3rd K, Sweeney C . Localization and modulation of ErbB receptor tyrosine kinases. Curr Opin Cell Biol. 2001; 13(2):125-30. DOI: 10.1016/s0955-0674(00)00188-5. View

Haryuni R, Watabe S, Yamaguchi A, Fukushi Y, Tanaka T, Kawasaki Y . Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation. Biochem Biophys Res Commun. 2019; 514(2):456-461. DOI: 10.1016/j.bbrc.2019.04.125. View

10.

Passaro A, de Marinis F . Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option. Transl Lung Cancer Res. 2018; 7(Suppl 2):S100-S102. PMC: 5943218. DOI: 10.21037/tlcr.2018.02.09. View

11.

Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi O, Elenius K . Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(2):259-68. DOI: 10.1007/s10911-008-9079-3. View

12.

Culouscou J, Plowman G, Carlton G, Green J, Shoyab M . Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor. J Biol Chem. 1993; 268(25):18407-10. View

13.

Hollmen M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T . Proteolytic processing of ErbB4 in breast cancer. PLoS One. 2012; 7(6):e39413. PMC: 3382207. DOI: 10.1371/journal.pone.0039413. View

14.

Plowman G, Culouscou J, Whitney G, Green J, Carlton G, Foy L . Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A. 1993; 90(5):1746-50. PMC: 45956. DOI: 10.1073/pnas.90.5.1746. View

15.

Yap T, Carden C, Kaye S . Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009; 9(3):167-81. DOI: 10.1038/nrc2583. View

16.

Bae J, Boggon T, Tome F, Mandiyan V, Lax I, Schlessinger J . Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc Natl Acad Sci U S A. 2010; 107(7):2866-71. PMC: 2840318. DOI: 10.1073/pnas.0914157107. View

17.

Donoghue J, Kerr L, Alexander N, Greenall S, Longano A, Gottardo N . Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response. Cancers (Basel). 2018; 10(8). PMC: 6116191. DOI: 10.3390/cancers10080243. View

18.

Tvorogov D, Sundvall M, Kurppa K, Hollmen M, Repo S, Johnson M . Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem. 2008; 284(9):5582-91. DOI: 10.1074/jbc.M805438200. View

19.

Dai X, Ma W, He X, Jha R . Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit. 2011; 17(8):RA177-190. PMC: 3539609. DOI: 10.12659/msm.881893. View

20.

Frey M, Edelblum K, Mullane M, Liang D, Polk D . The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology. 2008; 136(1):217-26. PMC: 2811086. DOI: 10.1053/j.gastro.2008.09.023. View